We are a clinical-stage company developing Antibody Radiation Conjugates for hematologic malignancies. Our lead application is targeted conditioning, intended to selectively deplete cells prior to Bone Marrow Transplant. I-131 apamistamab [Iomab-B] is being studied in the ongoing pivotal Phase 3 SIERRA trial for AML. Ongoing combination AML trials include Actimab-A (CD33) + CLAG-M and also + VEN. Underpinning our programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.